Clinical Trial Update: An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease [Phase 2]

View source ↗

Summary

Phase 2 open-label study of ANX005 in subjects with or at risk for Huntington's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• ANX005

Snippet

Sponsor: Annexon, Inc. | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED